Viatris submitted two drug applications to the FDA that were generics for three of Merck’s type 2 diabetes drugs that have exclusivity until Nov. 24, 2026, Merck said in a Sept. 22 news release. The second patent, which is for its diabetes drug Janumet, is set to expire in 2029.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
